Taragarestrant

Taragarestrant is an orally bioavailable selective [estrogen receptor degrader] developed by Inventis Bio for the treatment of estrogen receptor-positive breast cancer. Structurally similar to AZD9496, taragarestrant has demonstrated potent efficacy across multiple breast cancer cell lines expressing ER and related xenograft models. In preclinical studies, taragarestrant exhibited anti-tumor activity, warranting further clinical investigation.
A phase I study evaluated taragarestrant in females with ER+/HER2- advanced or metastatic breast cancer, both as monotherapy and in combination with the CDK4/6 inhibitor palbociclib. A phase III clinical trial has been initiated in China in patients with ER+/HER2- advanced or metastatic breast cancer.